Roche (RHHBY)
Quick facts
| Ticker | RHHBY (OTC) |
|---|
Marketed products
- Ocrevus · Neuroscience · revenue 6500
Ocrevus works by binding to the CD20 protein on B cells, marking them for destruction and reducing their ability to contribute to the disease process. - Vabysmo · Metabolic · revenue 5500
Vabysmo works by blocking the activity of a protein called vascular endothelial growth factor A. - Hemlibra · Hematology · revenue 4800
Hemlibra works by binding to and activating factor IXa, a protein involved in blood clotting, to bypass the need for factor VIII. - Mabthera · Oncology · revenue 3800
- Tecentriq · Oncology · revenue 3700
Tecentriq works by blocking a protein called PD-L1, which helps cancer cells hide from the immune system. - Xolair · Immunology · revenue 3200
- Herceptin · Oncology · revenue 2900
HER2-targeted antibody-drug conjugate delivering microtubule inhibitor DM1 to HER2-overexpressing cells. - Evrysdi · Neuroscience · revenue 2300
Evrysdi works by increasing the production of survival motor neuron protein. - Avastin · Oncology · revenue 2100
Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors. - Polivy · Oncology · revenue 1600
Polivy works by binding to a protein on the surface of cancer cells and releasing a toxin that kills the cell. - Gazyva · Oncology · revenue 1200
Gazyva binds to the CD20 antigen on B-lymphocytes, triggering their destruction. - Kadcyla · Oncology · revenue 900
Trastuzumab emtansine is a HER2-targeted antibody-drug conjugate that works by binding to the HER2 receptor and releasing a cytotoxic agent. - Alecensa · Oncology · revenue 700
Alecensa blocks the activity of the ALK protein, which is involved in the growth and spread of cancer cells. - Rozlytrek · Oncology · revenue 300
Rozlytrek works by blocking the activity of a specific protein called the nerve growth factor receptor. - Columvi · Oncology · revenue 300
Columvi works by binding to the CD20 protein on B-cell lymphoma cells, triggering an immune response to destroy the cancer cells. - Cotellic · Oncology · revenue 200
Cotellic works by blocking the activity of two proteins, BRAF and MEK, which are involved in the growth and spread of cancer cells. - Zelboraf · Oncology · revenue 100
Zelboraf blocks the activity of the B-raf protein, which is involved in cell growth and division. - Activase · Cardiovascular
- Xofluza · Infectious Disease
Xofluza works by inhibiting the endonuclease activity of the influenza virus, preventing it from replicating. - Xofluza · Infectious Disease
Xofluza works by inhibiting the endonuclease activity of the influenza virus's polymerase, preventing viral replication. - Ro 205720 · Pain
- Itovebi · Oncology
Itovebi works by blocking a specific enzyme called PIK3CA, which is involved in the growth and spread of cancer cells. - Taractan · Neuroscience
- Librax · Immunology
- Piasky · Immunology
Piasky works by blocking the action of the Complement C5 protein, which is involved in the immune system's response to foreign substances. - PIASKY · Other
- Zenapax · Immunology
- Pulmozyme · Infectious Disease
Pulmozyme breaks down DNA in the airways to reduce mucus viscosity. - Hu1124 · Immunology
- Fuzeon · Immunology
- Neorecormon · Oncology
Neorecormon works by binding to the erythropoietin receptor, mimicking the action of natural erythropoietin to stimulate red blood cell production. - VABYSMO · Metabolic
- Cytovene · Immunology
GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication. - COLUMVI · Oncology
- Boniva · Bone
- Lorfan · Rare Disease
- LTRA · Other
- Hexapen · Metabolic
Hexapen works by inhibiting bacterial cell wall synthesis, preventing the bacteria from producing a strong cell wall. - Noctan · Neuroscience
- Lunsumio · Oncology
Lunsumio works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: